Merrimack Pharmaceuticals Reports Second Quarter 2012 Financial Results
August 10, 2012 09:49 ET
|
Merrimack Pharmaceuticals
Completion of $105 Million IPO
Five Therapeutic Candidates in the Clinic, Each Planned to be Developed With a Companion Diagnostic From Proprietary Network Biology Platform
Over 15 Clinical...
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2012 Investor Conference Call
August 01, 2012 09:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2012 Investor Conference Call and webcast...
Merrimack Pharmaceuticals, Inc. [MACK] to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 24, 2012
July 23, 2012 17:14 ET
|
Merrimack Pharmaceuticals
Biotech company has five novel therapeutic oncology candidates in clinical development
MM-398 in Phase 3 clinical study for patients with metastatic pancreatic cancer who have previously failed...
Merrimack Pharmaceuticals Announces the Addition of Former Deloitte Global CEO James H. Quigley to Its Board of Directors
July 16, 2012 16:33 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 16, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of James Quigley, CEO emeritus of Deloitte Touche Tohmatsu, Limited (the...
William M. McClements Joins Merrimack Pharmaceuticals as Senior Vice President of Corporate Operations
July 09, 2012 17:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 9, 2012 (GLOBE NEWSWIRE) -- William M. McClements, a former executive at the Monitor Group, has joined Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) as Senior Vice President of...
Merrimack Pharmaceuticals and Cancer Treatment Centers of America(R) Partner in Multifaceted Collaboration to Advance Translational Research and Individualized Treatment
June 28, 2012 16:52 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 28, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) and the Cancer Treatment Centers of America® (CTCA) announced today that they have formed a...
Merrimack Announces Expansion of Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer
June 27, 2012 17:06 ET
|
Merrimack Pharmaceuticals
Expansion to Include MM-398 in Combination With 5-Fluorouracil and Leucovorin
Additional Arm Explores Broader Usage of MM-398 in a Setting Where Combination Therapy is Becoming More...
Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology Conference
June 26, 2012 16:59 ET
|
Merrimack Pharmaceuticals
Two Abstracts Selected for Oral Presentation
Three Posters to be Presented, Each on Different Examples of Applying the Network Biology Approach to Therapeutic Development
CAMBRIDGE, Mass., June...
Merrimack Pharmaceuticals Set to Join Russell 3000 Index
June 20, 2012 16:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 20, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its...
Merrimack Pharmaceuticals Announces the Addition of Cancer Research Pioneer John Mendelsohn, M.D. to Its Board of Directors
June 18, 2012 16:09 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 18, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of John Mendelsohn, M.D., past president of The University of Texas MD...